Overexpression of ARD1A gene reduces tumor size and number in mice

Mar 01, 2010

Overexpression of the ARD1A gene (arrest-defective protein 1225) in mice reduced the number and size of both primary tumors and metastases, researchers report in a new study published online March 1in the Journal of the National Cancer Institute.

ARD1A blocks the expression of VEGFA ( A), an important mediator of blood vessel growth in tumors. It regulates VEGFA expression indirectly by acetylating the transcription factor that induces VEGFA expression— hypoxia inducible factor 1(HIF-1α). Acetylation by ARD1A triggers degradation of HIF-1a, which blocks VEGFA expression and blood vessel proliferation in tumors.

To better understand ARD1A's effect on VEGFA expression and on tumor growth, Goo Taeg Oh, D.V.M., Ph.D., Division of Life and Pharmaceutical Sciences, Ewha Women's University, in Seoul, Korea, and colleagues injected mice that overexpressed mARDIA with human gastric cancer and mouse melanoma cells. They then measured growth, metastasis, and VEGFA expression.

The researchers found that the mARD1A-expressing mice had statistically significantly fewer intestinal polyps than controls. The growth and metastases of transplanted tumors were statistically significantly reduced in mice injected with mARD1A- overexpressing cells compared to injected with control cells. The group also confirmed that overexpression of mARD1A decreases VEGFA expression and microvessel density in tumors and that HIF-1α only needs to be acetylated at one site to be degraded.

The authors write: "…We conclude that mARD1A225 presents a novel target in the regulation of HIF-1a stability and may have potent therapeutic effects in combination with currently approved anti-VEGFA treatments such as bevacizumab."

Explore further: DNA alternative to Pap smear sparks medical debate (Update)

More information: jnci.oxfordjournals.org

add to favorites email to friend print save as pdf

Related Stories

New hope for cancer comes straight from the heart

Jan 05, 2009

Digitalis-based drugs like digoxin have been used for centuries to treat patients with irregular heart rhythms and heart failure and are still in use today. In the Dec. 16 issue of the Proceedings of the National Academy of ...

Recommended for you

DNA alternative to Pap smear sparks medical debate (Update)

13 hours ago

A high-tech screening tool for cervical cancer is facing pushback from more than a dozen American patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: ...

User comments : 0

More news stories

Low Vitamin D may not be a culprit in menopause symptoms

A new study from the Women's Health Initiative (WHI) shows no significant connection between vitamin D levels and menopause symptoms. The study was published online today in Menopause, the journal of The North American Menopa ...

Patent talk: Google sharpens contact lens vision

(Phys.org) —A report from Patent Bolt brings us one step closer to what Google may have in mind in developing smart contact lenses. According to the discussion Google is interested in the concept of contact ...

Tech giants look to skies to spread Internet

The shortest path to the Internet for some remote corners of the world may be through the skies. That is the message from US tech giants seeking to spread the online gospel to hard-to-reach regions.

Wireless industry makes anti-theft commitment

A trade group for wireless providers said Tuesday that the biggest mobile device manufacturers and carriers will soon put anti-theft tools on the gadgets to try to deter rampant smartphone theft.